Mint Explainer: What the weight-loss drug frenzy means for pharma sector and for you

The price war that hit India’s weight loss and diabetes drug market after Semaglutide lost patent protection has pushed innovator Novo Nordisk to slash prices of Ozempic and Wegovy. Cheaper generic drugs could expand access, but concerns about abuse are growing, prompting regulatory scrutiny.